Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Kiyotaka Uchiyama(Japanese Red Cross Medical Center), Kaori Hayashi(Akita University), Naoki Washida(Keio University), Tomoki Nagasaka(Keio University), Takashin Nakayama(Keio University Hospital), Ei Kusahana(Keio University), Shintaro Yamaguchi(Keio University), Daisuke Kamano(Japanese Red Cross Medical Center), Matsuhiko Hayashi(Keio University), Rina Takahashi(Keio University), Eriko Yoshida Hama(Keio University), Akane Yanai(New Tokyo Hospital), Rena Sumura(Japanese Red Cross Medical Center), Takahiro Kasai(International University of Health and Welfare), Takahide Kimura(International University Of Health And Welfare Atami Hospital), Jun Yoshino(Shimane University Hospital), Tatsuhiko Azegami(Keio University), Hiroshi Itoh(Yamaguchi University), Yoshitaka Ishibashi(Japanese Red Cross Medical Center), Takeshi Kanda(Shimane University Hospital), Takaya Tajima(Keio University), J. Ito(International University of Health and Welfare), Koji Hosoya(International University of Health and Welfare), Ryoichi Shirai(Japanese Red Cross Medical Center)
Cited by 16
Related Papers
Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice
|Cell Metabolism|2011|1.3k
Circadian Clock Feedback Cycle Through NAMPT-Mediated NAD <sup>+</sup> Biosynthesis
|Science|2009|1.1k
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
|Cell Metabolism|2017|1k